TheStreet Ratings

10 Best Biotech Stocks for 2016 - Top Stocks - TheStreet Ratings

Top Rated Stocks

Every day TheStreet Ratings produces a list of the top rated stocks, by industry. The following biotech stocks are rated highest by our value-focused model. This list will be updated as upgrades and downgrades occur.

Equity Top: Biotechnology

Source: TheStreet Ratings

Best Investments for

Biotechnology News

Using Northwest Bio as an example, I'm going to teach you how to read clinical trial data to find red flags and bad stuff biotechs don't want you to see.
9/24/16 3:00PM
An Alzheimer's drug under development by Danish pharma Lundbeck failed a pivotal phase III study and Axovant suffered collateral damage.
9/22/16 12:32PM
When an experimental glaucoma drug is only marginally effective, one way to produce positive clinical trial results is to enroll patients with borderline glaucoma.
9/21/16 6:30AM
TheStreet's Adam Feuerstein answers reader questions about Sarepta Therapeutics and its newly approved drug Exondys 51 for Duchenne muscular dystrophy.
9/20/16 6:55AM
Sarepta, its shareholders, biotech investors, and Duchenne patients and their families have been waiting years for today's news.
9/19/16 2:43PM
Sarepta's largest shareholder talks about the company's future following FDA approval of its Duchenne muscular dystrophy drug.
9/19/16 12:54PM
The FDA told Spectrum not to seek approval for its bladder cancer drug. Spectrum filed anyway but never told investors about the FDA warning.
9/16/16 11:47AM
Collectively, the data will give investors a clearer measure of Gilead's internal drug development efforts outside of its core hepatitis C and HIV strengths.
9/15/16 11:17AM
The departure of an important eteplirsen critic from the FDA could be a sign that the internal agency debate over Sarepta's drug is coming to an end.
9/14/16 12:55PM
How will biotech stocks end the year? Will FDA approve Sarepta's drug? Will Gilead finally buy another company?
9/12/16 8:35AM
Important clinical trial results in Alzheimer's, cancer and Crohn's disease and a big FDA decision for Sarepta are expected before the end of the year.
9/9/16 9:14AM
Bluebird Bio removed a significant concern investors had about its gene therapy manufacturing process, sending shares higher Thursday.
9/8/16 10:36AM
Retrophin announced positive results from a study in which patients with a rare kidney disease responded to treatment with its experimental drug sparsentan.
9/7/16 8:35AM
Celgene owns the rights to the Agios drug known as AG-221 under an existing partnership.
9/7/16 8:10AM
CEO Brent Saunders said Allergan will act differently, pledging to limit price increases on drugs the company sells as part of a 'commitment to innovation, access and responsible pricing ideals.'
9/6/16 9:20AM